These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27018750)

  • 1. Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.
    Johnson KJ; Zoellner NL; Gutmann DH
    Cancer Epidemiol; 2016 Jun; 42():53-9. PubMed ID: 27018750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1.
    Porcelli B; Zoellner NL; Abadin SS; Gutmann DH; Johnson KJ
    Fam Cancer; 2016 Apr; 15(2):301-8. PubMed ID: 26666764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
    Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
    Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.
    Sharif S; Ferner R; Birch JM; Gillespie JE; Gattamaneni HR; Baser ME; Evans DG
    J Clin Oncol; 2006 Jun; 24(16):2570-5. PubMed ID: 16735710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas.
    Johnson KJ; Fisher MJ; Listernick RL; North KN; Schorry EK; Viskochil D; Weinstein M; Rubin JB; Gutmann DH
    Fam Cancer; 2012 Dec; 11(4):653-6. PubMed ID: 22829012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
    Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
    Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving outcomes for neurofibromatosis 1-associated brain tumors.
    Brossier NM; Gutmann DH
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.
    Avery RA; Mansoor A; Idrees R; Trimboli-Heidler C; Ishikawa H; Packer RJ; Linguraru MG
    Neurology; 2016 Dec; 87(23):2403-2407. PubMed ID: 27815398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive central nervous system involvement in optic pathway gliomas in neurofibromatosis type 1.
    Shaikh F; Johnston D; Michaud J; Hurteau J; Vassilyadi M; Keene D
    Pediatr Blood Cancer; 2011 Oct; 57(4):688-6690. PubMed ID: 21465640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
    Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
    Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
    Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
    Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
    Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1.
    Avery RA; Mansoor A; Idrees R; Biggs E; Alsharid MA; Packer RJ; Linguraru MG
    Neurology; 2016 Jun; 86(24):2264-70. PubMed ID: 27170570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromatosis type 1 and sporadic optic gliomas.
    Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
    Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
    J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
    Listernick R; Ferner RE; Liu GT; Gutmann DH
    Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm.
    Caen S; Cassiman C; Legius E; Casteels I
    Eur J Paediatr Neurol; 2015 Jul; 19(4):415-22. PubMed ID: 25797697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte Subpopulations in Patients With Neurofibromatosis Type 1-associated Optic Pathway Gliomas and Plexiform Neurofibromas.
    Marjanska A; Kubicka M; Kurylo-Rafinska B; Jatczak-Gaca A; Wysocki M; Styczynski J
    Anticancer Res; 2019 Nov; 39(11):6389-6392. PubMed ID: 31704872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
    Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE; Nuding MA
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.